glp-1 drug made by eli lilly Lilly's $1 Trillion Boom: Inside Dave Ricks' Weight-Loss Bet Lilly to Boost Obesity Drug

doi: 10.1016/j.lfs.2020.117996 4 ScheltensPDe StrooperBKivipeltoMHolstegeHChtelatGTeunissenCEet al

Food and Drug Administration (FDA) make it clear that Novo Nordisk knew or should have known about these potential risks, yet failed to conduct thorough research on the semaglutide drugs side effects, placing its desire for profits before consumer safety

doi: 10.1016/j.jcjd.2024.08.002

Some muscle loss is normal during weight loss, but the goal is to keep as much strength and function as possible

Infusions that achieve supraphysiological GIP concentrations fail to elicit a significant insulin secretory response in patients with T2DMs

There is currently no evidence of harmful interactions between allulose and GLP-1 receptor agonists, though the combination has not been systematically studied